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ABSTRACT
Objective: To assess the costs and cost-effectiveness of vor-
iconazole in comparison to conventional amphotericin B
(CAB) for the treatment of invasive aspergillosis in Germany.
Methods: The cost-effectiveness of voriconazole in compar-
ison to CAB was evaluated with a lifetime Markov model,
focusing on the long-term survival of patients treated for
invasive aspergillosis. Long-term survival was extrapolated
from  survival  after  12 weeks  of  treatment,  obtained  from
a randomized aspergillosis study. Information on medical
resource consumption and treatment pathways were
obtained from this study and an expert committee. With
probabilistic analysis the cost-effectiveness of voriconazole
compared with amphotericin B was analyzed and expressed
in incremental costs per life-weeks gained. The evaluation
was performed from a limited societal perspective (both
inpatient and outpatient costs) and hospital perspective (only
inpatient costs).
Results: Average survival of patients treated with voricona-
zole was 174.4 life-weeks (95% conﬁdence interval [CI]
159.4–191.3), compared with 119.4 life-weeks (95% CI
106.4–132.3) for amphotericin B. With voriconazole, the
mean total costs per patient were €30,026 (95% CI €23,118–
37,947) compared with €26,669 for amphotericin B (95% CI
€21,259–34,263) from the limited societal perspective. The
corresponding incremental cost-effectiveness ratio was €62
per life-week gained (i.e., €3224 per life-year gained). Hos-
pital costs were approximately 90% of the mean total costs.
Conclusions: In the treatment of invasive aspergillosis, vor-
iconazole is cost-effective in comparison to amphotericin B.
Hospital costs are comparable for both treatments and are
expected to be reimbursed based on the German diagnosis-
related groups (DRG) system 2005.
Keywords: cost-effectiveness analysis, diagnosis-related
groups, invasive aspergillosis, reimbursement.
Introduction
Invasive fungal infections are an increasingly impor-
tant cause of morbidity and mortality particularly in
patients with hematologic malignancies. Important
risk factors are prolonged severe neutropenia (neu-
trophil count of more than 500/μL for more than
10 days), hematopoietic stem cell transplant (HSCT),
and subsequent intensive chemotherapy after previous
fungal infections [1–3]. One of the most common
causes of invasive fungal infections is Aspergillus spe-
cies [4–7]. The incidence of Aspergillus infection varies
according to the underlying condition, but is most fre-
quently observed among severely neutropenic patients.
The fatality rate of invasive aspergillosis is approxi-
mately 50% to 60% [1,8].
Amphotericin B deoxycholate and voriconazole are
licensed as ﬁrst-line therapy for treatment of life-
threatening invasive fungal infections, including inva-
sive aspergillosis [1,9]. Until 2002 conventional
amphotericin B (CAB) was considered as the standard
choice of ﬁrst-line treatment in Germany. The major
drawback of CAB is the poor tolerability and the
severity of the toxic effects, with nephrotoxicity as the
most signiﬁcant adverse event. Lipid formulations of
amphotericin B have signiﬁcantly lower rates of neph-
rotoxicity, however, the hospital acquisition costs are
very high. Therefore, these formulations are reserved
as second-line therapy after failure or intolerance with
CAB.
Voriconazole, a broad-spectrum triazole that is
active against Aspergillus species, has been introduced
in 2003 as an alternative to CAB. In a randomized con-
trolled trial, ﬁrst-line therapy of invasive aspergillosis
with voriconazole in immunocompromised patients
was compared with CAB. Voriconazole showed supe-
rior efﬁcacy with higher response rates, better survival,
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and fewer drug-related adverse events [10]. For these
reasons, voriconazole is recommended as primary
treatment of aspergillosis in Germany [1]. Neverthe-
less, CAB is still widely used mainly because of its
lower drug acquisition costs.
The direct medical costs for the treatment of inva-
sive aspergillosis are often high, and consist of the
following factors: antifungal therapy costs, costs of
treating adverse events, and additional costs related to
hospital resources [11]. Because patients with aspergil-
losis are most often on medications for their underly-
ing disease, the treatment of the invasive fungal
infection results in an increased use of medical
resources and costs in comparison to patients with the
same underlying medical condition but without the
fungal infection. Wilson and colleagues [11] estimated
that the average inpatient cost related to an aspergil-
losis infection was about $38,000. These costs varied
by underlying condition from about $31,000 among
HIV patients to about $86,000 among transplant
patients. Because costs of treatment of fungal infec-
tions are coupled with limited health-care resources it
is of interest to perform an economic evaluation for the
primary treatment of aspergillosis in Germany. In par-
ticular, we compared the current standard treatment,
voriconazole, with the previous standard treatment,
that is, CAB.
In Germany the former hospital ﬁnancing system,
which consisted partly of per-diem rates and partly of
per-case rates, has been replaced by a case-mix system
based on diagnosis-related groups (G-DRGs) in an
attempt to improve efﬁciency in hospitals. For patients
with an invasive aspergillosis the basic DRG reﬂects
the underlying condition (e.g., HSCT or hematologic
cancer as primary diagnosis) followed by a value for
the patient clinical complexity level (PCCL) for the
infection. With the introduction of the new DRG cat-
alog of 2005 certain drugs have been granted separate
reimbursement (“Zusatzentgelte”) in addition to the
DRG reimbursement. This regulation applies to the
antifungal drugs voriconazole, lipid amphotericin B,
and caspofungin. Because the treatment costs of inva-
sive aspergillosis are expected to be high in Germany,
the question that arises is whether the reimbursed costs
based on the current DRG system (2005) cover the
actual costs caused by invasive aspergillosis patients.
The objective of the current study is to perform
an economic analysis of voriconazole as ﬁrst-line
treatment of invasive aspergillosis in Germany. First, a
cost-effectiveness analysis is performed by which the
treatment with voriconazole as ﬁrst-line treatment is
compared with the previous situation where CAB was
used as ﬁrst-line therapy. Second the costs of treatment
for invasive aspergillosis from the hospital perspective
are compared with the reimbursed costs based on the
DRG system. Because the majority of treatment costs
are the inpatient costs and the recent changes in reim-
bursement system reﬂect the inpatient situation, this
comparison of costs and charges is limited to the inpa-
tient costs.
Methods
A “lifetime” Markov model was constructed to eval-
uate the cost of treatment and cost-effectiveness of vor-
iconazole in comparison to CAB in Germany. For each
treatment, patients were allowed to continue on ther-
apy, or switch to other licensed antifungal agents
(OLAT) in the case of toxicity or lack of effectiveness.
The 12-week Pﬁzer Global Comparative Aspergillosis
(GCA) (307/602) study [10], a randomized controlled
trial comparing voriconazole with CAB, was the pri-
mary source of data for the development of the model.
Experts provided additional data and validation of the
model assumptions.
Perspective
The cost-effectiveness analysis was performed from a
societal perspective and a hospital perspective, as
depicted in Table 1. Only direct medical costs associ-
ated with the treatment of invasive aspergillosis were
included. The societal perspective included both inpa-
tient and outpatient costs, the hospital perspective only
included inpatient costs. Indirect medical costs and
costs for treatment of the underlying disease were not
included because the interest was in the generated
Table 1 Perspective of economic evaluations
Societal perspective (direct costs) Hospital perspective, costs Hospital perspective, charges*
Analysis Cost-effectiveness analysis that includes
both inpatient and outpatient costs
• Cost-effectiveness analysis
• Inpatient costs
Hospital charges: calculation of 
reimbursed inpatient costs based on 
DRG system
Calculation 
of inpatient
costs
Real unit costs (extracted from DRG and
tariffs from EBM and Gelbe Liste as a 
proxy for real unit costs) multiplied by
health-care resource consumption
Real unit costs (extracted from DRG and
tariffs from EBM and Gelbe Liste as a 
proxy for real unit costs) multiplied by
health-care resource consumption
Charges estimated with DRG of 
underlying condition, length of stay
and total dosage of voriconazole, 
caspofungin and lipid amphotericin B
Calculation of
outpatient
costs
Unit costs (EBM, Gelbe Liste as proxy for 
real unit costs) multiplied with health-
care resource consumption
— —
*German DRG 2005.
DRG, diagnosis-related group; EBM, Einheitlicher Bewertungsmaßstab.
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additional costs of treating patients with aspergillosis.
Indirect nonmedical costs were not included because
the assumption was made that patients with aspergil-
losis were not employed because of the severity of the
underlying disease. All costs were calculated in 2005
euros. Calculation of reimbursement of inpatient costs
due to treatment of invasive aspergillosis (i.e., hospital
charges) was based on the 2005 German DRG system.
Population
The model simulated a cohort of patients with proven
or probable aspergillosis in patients with allogenic/
autologous hematopoietic cell transplantation, acute
leukemia, other hematologic cancers, solid organ trans-
plants, AIDS/HIV, and high-dose corticosteroid recip-
ients; the most frequent underlying medical conditions
in the GCA (307/602) study. Forty percent of the mod-
eling population was assumed neutropenic. For pur-
poses of this analysis, we assumed the mean weight of
a patient to be 70 kg (as in the clinical study) [10].
Model Structure
The model consisted of a 12-week decision tree fol-
lowed by 1-week Markov cycles simulating the lifetime
future course of patients (See Fig. 1).
Twelve-week  decision  tree. The decision tree, as
described by Wenzel et al. [12], depicts the treatment
pathways of voriconazole and CAB as observed in the
GCA (307/602) study [10] during a 12-week follow-
up. Immunocompromised patients with invasive
aspergillosis enter the tree and are initially treated with
either voriconazole or CAB. Patients who experience
severe early toxicity (within 3 days) were consequently
switched to OLAT. Patients without an early switch
followed one of the following treatment pathways:
continue treatment with no therapy switch; switch to
other antifungal therapy due to nonresponse to ﬁrst-
line therapy; switch antifungal therapy due to major
renal toxicity; switch antifungal therapy due to major
hepatotoxicity; switch therapy due to other reasons.
Markov cycles for lifetime course. In the GCA (307/
602) study treatment success was evaluated at
12 weeks follow-up. Nevertheless, the 12-week deci-
sion tree was extended with 1-week Markov cycles to
simulate long-term follow-up until death to obtain an
estimate of the survival times for both voriconazole
and CAB. The Markov cycles consisted of the follow-
ing health states: death, treatment failure, and treat-
ment success. Patients that were dead at 12 weeks were
transferred to the absorbing state “Death.” Patients
with a response at 12 weeks started the Markov proc-
ess as a “success.” Successfully treated patients at
12 weeks could only stay in the “success” state (i.e.,
stay alive), or experience a transition to the “death”
state. Patients with a nonsuccessful response at
12 weeks who did not die entered the Markov process
as a “Failure.” These patients could remain a failure
over the following weeks, become a success, or die.
Figure 1 Decision analytic model of treatment of aspergillosis with voriconazole and conventional amphotericin B.
12 week follow-up Week 13 and following 
Failure
Success
Dead
Failure
Success
Dead
Success
Dead
No switch
Nonresponse switch
 [+] 
Renal toxicity switch
 [+] 
Hepatotoxicity switch
 [+] 
Other switch
 [+] 
No early switch
Early switch
 [+] 
Voriconazole
Amphotericin B
 [+] 
Invasive aspergillosis 
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Assumptions  of  the  model  structure. The following
assumptions and simpliﬁcations were made regarding
the model structure. These were validated by the
experts:
• The model assessed a single episode of invasive
aspergillosis. Patients with a nonresponse, or
severe toxicity only experienced a single switch to
another antifungal therapy. This switch occurred
within 12 weeks of treatment and only in the
hospital.
• Successful treatment has been deﬁned as either a
complete or partial resolution of signs and symp-
toms of aspergillosis as deﬁned in the GCA (307/
602) study. For the Markov cycles the probability
of successful treatment was assumed to be con-
stant per week.
• Patients with a successful outcome experience the
same survival as observed among patients with the
same underlying condition that never experienced
aspergillosis.
• A full course of initial therapy (including resource
use) as observed in the 12 weeks of the GCA (307/
602) study was assigned to all nonswitch patients
independent of their outcome at 12 weeks (i.e.,
successes, failures, and death).
• Nonswitch patients that were a failure at week 12
and were still alive continued to receive treatment
from week 13 onwards (the Markov cycles) until
they died or experienced a successful outcome.
• For the switch patients a shortened course of the
ﬁrst-line therapy and then a full course of the sec-
ond therapy was assigned to all patients independ-
ent of the outcome of the treatment at 12 weeks.
• Only switch patients that were a failure at week
12 and were still alive continued to receive treat-
ment with the switch therapy from week 13
onwards (the Markov cycles) until they died or
experienced a successful outcome.
Input Parameters
Treatment patterns. For voriconazole and CAB infor-
mation on switch probabilities, proportional switch
distributions, and time to switch were based on the
results of the GCA (307/602) study and adapted to the
local German situation by the experts. In Table 2 the
switch probabilities, with the corresponding standard
errors, for the treatment pathways after initiating
treatment with voriconazole and CAB are presented.
In Table 3 the proportional switch distributions as
used in the model are presented. Step-down therapy
from CAB to oral itraconazole was not considered a
switch. In the model time to early switch due to severe
toxicity was deﬁned 3 days, and time to switch for
other reasons was deﬁned as 26 days for voriconazole
and 16 days for CAB, based on observed results of the
GCA (307/602) study.
Effectiveness. For voriconazole and CAB information
on the transition probabilities for success, failure, and
mortality at week 12, and corresponding standard
errors, for each treatment pathway were deducted
from the treatment pathway-speciﬁc success rates from
the GCA (307/602) study. To obtain information on
the mortality rate for each treatment pathway the ratio
between the number of patients that have died among
nonsuccessfully treated patients for both voriconazole
followed by OLAT and CAB followed by OLAT
(61.8% and 61.5%, respectively) was multiplied with
the proportion of nonsuccessfully treated patients in
each treatment pathway. The 12-week transition prob-
abilities for success, failure, and mortality were the
starting probabilities for the Markov process reﬂecting
long-term follow-up.
Under the assumption that time to success and mor-
tality were both exponentially distributed with a con-
stant success and mortality probability per week, the
transition probabilities for success, failure, and death
Table 2 Toxicity and nonresponse transition probabilities with standard error as used in the model
Voriconazole
Conventional amphotericin B
(with step-down to oral itraconazole) 
Transition probability (SE) Source Transition probability (SE) Source
Early switch 0.028 GCA (307/602) 0.195 GCA (307/602) [10]
(0.01) (0.03)
No early switch 0.972 “ 0.805 “
(0.01) (0.03)
No switch 0.736 “ 0.327 “
(0.04) (0.04)
Nonresponse switch 0.136 “ 0.186 “
(0.03) (0.03)
Renal toxicity switch — “ 0.383
(0.04)
“
Hepatotoxicity switch 0.029 “ 0.029 “
(0.01) (0.01)
Other switch 0.100 “ 0.075 “
(0.02) (0.02)
GCA, Global Comparative Aspergillosis.
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per week from week 13 onwards, were deducted from
the 12-week transition probabilities. In Table 4 the
transition probabilities per week used to parameterize
the Markov cycles to simulate the future course of fail-
ure patients at week 12 are presented. Another
assumption regarding the effectiveness inputs was that
successfully treated patients have the same mortality
rate as observed among patients with the same under-
lying medical conditions who never experienced
aspergillosis. The mortality probability was based on
an assumed median survival of 3.5 years for the under-
lying conditions (about 35% 5-year survival), that is, a
mortality probability per week of 0.0039 [13].
Health-care  resource  consumption. Based on the
results of the GCA (307/602) study as well as the
experts we obtained estimates for health-care resource
consumption for duration of 12 weeks. In the calcula-
tion of the average resource consumption patients that
died during the ﬁrst 12 weeks were taken into account.
As a result differences in resource consumption for the
CAB and voriconazole arm observed were partly
driven by differences in mortality. The resource con-
sumption from week 13 onwards was extrapolated
from these 12-week results. For all resource consump-
tion parameters the uncertainty reﬂected a range where
the lowest estimate was 80% of the mean, and the
highest estimate was 120% of the mean.
Antifungal  therapy  in  the  ﬁrst  12 weeks. Based on
the GCA (307/602) study, we assumed an average of
14 days of IV treatment and 50 days of oral treatment
for all nonswitch patients on voriconazole (independ-
ent of their outcome at 12 weeks), and for nonswitch
patients on CAB we assumed on average 21 days of IV
treatment and 7 days of step-down therapy with itra-
conazole in the 12-week decision tree. For OLAT, that
is, itraconazole, lipid amphotericin B, and caspofun-
gin, the duration of therapy was derived from the
experts. Itraconazole was assumed to have the same
duration of IV treatment and oral treatment as vori-
conazole. Lipid amphotericin B and caspofungin were
Table 3 Proportional switch distributions
Voriconazole (%)
Conventional amphotericin B
(with step-down to oral itraconazole) (%)
Early switch
Switch to amphotericin B 26.20 2.10
Switch to lipid amphotericin B 73.80 40.80
Switch to itraconazole 0.00 48.60
Switch to caspofungin 0.00 8.50
Switch due to nonresponse
Switch to amphotericin B 30.60 9.40
Switch to lipid amphotericin B 32.90 15.40
Switch to itraconazole 0.00 51.30
Switch to caspofungin 36.50 23.90
Switch due to severe renal toxicity
Switch to amphotericin B — 0.00
Switch to lipid amphotericin B — 29.60
Switch to itraconazole (voriconazole when on itra at begin) — 50.40
Switch to caspofungin — 20.00
Switch due to severe hepatotoxicity
Switch to amphotericin B 33.00 5.7
Switch to lipid amphotericin B 15.00 24.3
Switch to itraconazole (voriconazole when on itra at begin) 0.00 40.00
Switch to caspofungin 52.00 30.00
Switch due to other reasons
Switch to amphotericin B 8.40 7.10
Switch to lipid amphotericin B 10.00 15.70
Switch to itraconazole (voriconazole when on itra at begin) 61.30 20.00
Switch to caspofungin 20.30 57.20
Table 4 Transition probabilities per week (with standard
error)*
Voriconazole
Conventional amphotericin B
(with step-down to 
oral itraconazole)
Success
Early switch 0.056 (0.02) 0.040 (0.02)
No switch 0.069 (0.02) 0.019 (0.01)
Nonresponse switch 0.025 (0.01) 0.018 (0.01)
Renal toxicity switch 0.000 (0.00) 0.040 (0.02)
Hepatotoxicity switch 0.056 (0.02) 0.040 (0.02)
Other switch 0.069 (0.02) 0.080 (0.02)
Mortality
Early switch 0.025 (0.01) 0.039 (0.02)
No switch 0.030 (0.01) 0.055 (0.02)
Nonresponse switch 0.049 (0.02) 0.055 (0.02)
Renal toxicity switch 0.000 (0.00) 0.038 (0.02)
Hepatotoxicity switch 0.030 (0.01) 0.076 (0.02)
Other switch 0.026 (0.01) 0.022 (0.01)
Failure (=Continue treatment)
Early switch 0.914 (0.02) 0.921 (0.02)
No switch 0.906 (0.02) 0.926 (0.02)
Nonresponse switch 0.925 (0.02) 0.927 (0.02)
Renal toxicity switch 0.000 (0.00) 0.921 (0.02)
Hepatotoxicity switch 0.914 (0.02) 0.884 (0.03)
Other switch 0.905 (0.02) 0.898 (0.03)
*Probabilities were extracted from 12-week results as reported by Herbrecht et al.
[10] assuming an exponential distribution of survival and time to success.
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assumed to have 21 days of IV treatment and 50 days
step-down to oral itraconazole.
Duration of hospitalization and outpatient visits in the
12-week decision tree. Based on the GCA (307/602)
study we assumed 27 days of hospital stay including
0.5 day in the intensive care unit (ICU) for nonswitch
patients on voriconazole in the 12-week decision tree.
For nonswitch patients on CAB we assumed 21 days
of hospital stay including 0.5 day in the ICU. Patients
that died during the ﬁrst 12 weeks were taken into
account, which explain the observed differences in
length of stay between CAB and voriconazole. When
patients are discharged from the hospital, antifungal
treatment is continued in the outpatient setting with
assumed three outpatient visits for CAB and two for
other therapies. The length of stay and number of out-
patient visits with voriconazole and CAB, after a
switch was assumed to be the same as for a nonswitch
therapy  with  these  antifungals.  Lipid  amphotericin  B
and caspofungin were assumed to have the same length
of stay and number of outpatient visits as
voriconazole.
Prophylaxis, treatment, and monitoring of side effects
of antifungal therapy in the 12-week decision tree.
Information on prophylaxis, treatment, and monitor-
ing of side effects of antifungal therapy was obtained
from  the  expert  panel.  Paracetamol  was  given  for
the duration of IV antifungal treatment. Neutropenic
patients (40% of the population) received ceftazidime,
meropenem, or piperacillin-tazobactam for the dura-
tion of IV treatment in a 2 : 1 : 1 proportion. The fre-
quency of both complete blood count and liver
function testing was assumed to be twice a week dur-
ing the inpatient phase of treatment. Urine analysis
was performed once per week.
Screening for fungal infection in the 12-week decision
tree in the 12-week model. As recommended by the
expert panel, it has been assumed that ELISA was per-
formed two times a week when the patient was in the
hospital. Chest x-rays were performed once per week.
Computed tomography (CT)-scans were performed
two times during the inpatient phase, and bronchoal-
veolar lavage and a fungal culture were performed
once.
Resource consumption per week used in the Markov
cycles. Failure patients at week 12 continued treat-
ment. The medical resource consumption per week
from week 13 onwards for failure patients was calcu-
lated as follows. Individual data on hospital stay up to
week 12 from the GCA (307/602) study were extrap-
olated after week 12 by ﬁtting an exponential distri-
bution, and it was observed that the weekly transition
probability of hospital discharge was comparable to
the weekly transition probability of failure to success.
In addition, at week 12 about 50% of the failure
patients remained hospitalized. Combining these two
probabilities was the basis for estimating that from
week 13 onwards 50% of the failure patients each
week are treated in the hospital with the antifungal
therapy (including treatment of side effects and screen-
ing) administered at week 12. The remaining 50% are
treated in an outpatient setting and continued with
oral antifungal treatment administered at week 12.
Unit Costs
The costs per unit of medical resource consumption
are presented in euros (2005) for the societal perspec-
tive and hospital perspective in Table 5.
The unit costs related to stay and nursing were
extracted from detailed information from the G-DRG
provided by the Institut für das Entgeltsystem im
Krankenhaus (InEk) [14]. Rational for usage of these
data is that German DRGs are based on real cost cal-
culation and provide a solid estimate to address
resource (e.g., nursing requirements) use for speciﬁc
indications. DRGs related to treatment of the frequent
underlying conditions of invasive aspergillosis were
identiﬁed. The DRG data do not explicitly reﬂect the
true costs of aspergillosis therapy. But according to the
advice provided by the clinical experts, resource use of
the identiﬁed “proxy DRGs” represent a good estimate
for real costs of aspergillosis therapy based on a large
sample of patients from the DRG database. From the
identiﬁed DRGs it was determined which DRGs best
reﬂect the treatment of invasive aspergillosis in terms
of nursing intensity and hospital department, and for
which the vast majority of costs (more than 80%) were
driven by normal care, in contrast to intensive care.
The basic costs and costs of normal care, excluding
drug costs and medical device costs, in combination
with the length of stay corresponding to the DRGs
were used to calculate an average hospital cost per day
for normal care. To obtain these unit costs for inten-
sive care two DRGs were chosen with comparable
costs related to normal care but different costs related
to intensive care. The difference in basic and intensive
care costs, excluding drug costs and medical device
costs, were divided by the difference in corresponding
length of stay to obtain the unit hospital costs. Other
unit cost of medical resource consumption was
obtained from the Einheitlicher Bewertungsmaßstab
(EBM) [15], used as a proxy for real costs, and Gelbe
Liste for drugs [16].
Analysis
Calculation  of  costs  in  12-week  decision  tree. Sim-
ilar to Wenzel et al. [12] the treatment costs as used in
the 12-week decision tree were calculated as follows:
The “cost of a full course of ﬁrst-line treatment
without a switch” included costs for antifungal ther-
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apy, diagnosis, monitoring, and treatment of side
effects, screening for fungal infections, hospitalization,
and outpatient care. In addition, the “mean daily hos-
pital costs” were calculated.
The “cost of a full course of switch therapy” also
included cost for antifungal therapy, diagnosis, moni-
toring and treatment of side effects, screening for fun-
gal infections, hospitalization, and outpatient care.
With the decision tree the “costs for each type of
switch” (i.e., early switch, nonresponse switch, etc.)
were calculated by adding the weighted mean “costs of
a full course of switch therapy” using the proportional
switch distribution in Table 3 to the “costs of ﬁrst-line
treatment up to the switch.” The “costs of ﬁrst-line
treatment up to the switch” were calculated by multi-
plying the “mean daily hospital costs” by the number
of days on ﬁrst-line therapy until the switch.
To obtain the “total costs for each treatment arm”
(i.e., voriconazole, CAB, and itraconazole) the “costs
for each type of switch” were weighted using the
switch proportions in Table 2.
Calculation of costs in the Markov cycles. For each
antifungal therapy administered at week 12 the “Cost
of course of treatment per week” was determined by
calculating the average of the “weekly hospital cost”
and “weekly outpatient treatment costs.” It was
assumed that per week 50% of the patients were
treated on an inpatient basis, and the other on an out-
patient basis. For each type of switch the “total treat-
ment costs per week” were calculated by the weighed
mean of the “cost of course of treatment per week”
using the proportional switch distributions (Table 3).
Calculation of reimbursed hospital costs based on G-
DRG system. Hospital charges for the invasive
aspergillosis infections based on the G-DRG 2005
were estimated as follows: The additional length of
stay in hospital due to an aspergillosis infection was
estimated from the model. From the DRGs corre-
sponding to hematologic cancer, stem cell transplants
(autogen and allogen), and HIV, the length of stay due
to these underlying conditions was obtained as well as
average reimbursed costs, that is, the charges for
patients only suffering from the underlying condition.
The sum of the additional length of stay resulting from
the infection and the length of stay associated with the
underlying condition was used to calculate the total
length of stay. This total length of stay was used to
determine the reimbursed cost for patients with the
infection and underlying disease using G-DRG 2005.
The difference between these charges, for the reim-
bursement of costs related to the underlying condition
with an infection, and the average charges of the
Table 5 Description costs from limited societal perspective and hospital perspective
Details
Cost per day or 
cost per unit (€) Source
Antifungal therapy
Conventional amphotericin B 1 mg/kg/day IV 118.65 Gelbe Liste Pharmindex/clinical expert [16]
AmBisome (lipid amphotericin B) 3 mg/kg/day IV 821.91 “
Itraconazole 400 mg oral/day 17.304 “
400 mg/day IV 305.616 “
600 mg/day IV 458.424 “
Caspofungin 70 mg/day/kg IV 779.42 “
50 mg/day/kg IV 614.78 “
Voriconazole 2 × 200 mg oral/day 116.61 “
8 mg/kg/day IV 579.52 “
12 mg/kg/day IV 869.27 “
Prophylaxis and treatment of side effects of antifungal therapy “
Paracetamol 1 g/day IV 0.13 “
Ceftazidime 5 g/day oral 119.2 “
Meropenem 60 mg/kg/day IV 181.6 “
Pethidine 25 mg/day IV 0.83 “
Hydrocortisone 25 mg/day IV 0.5387 “
Piperacillin/Tazobactam 4 g/0.5 g tds 33.98 “
Monitoring for side effects
Complete blood count 5.83 EBM Einheitlicher Bewertungsmaßstab [15]
Urinalysis Nonautomated, with microscopy 5.48 “
Liver function test 11.63 “
Screening for fungal infection
Galactomannan assay ELISA 21.63 “
Chest x-ray 52.03 “
CT scan 294.12 “
Bronchoalveolar lavage 150.12 “
Fungal culture Nonblood 9.83 “
Hospitalization/outpatient care
Intensive care unit per diem 1010 Extracted from G-DRG 2005 [14]
Inpatient per diem 200 “
Outpatient specialist visit 33.11 EBM Einheitlicher Bewertungsmaßstab [15]
CT, computed tomography; tds, total dissolved solids.
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underlying condition were assumed the charges for the
aspergillosis infection because of additional length of
stay.
For patients treated with voriconazole, caspofungin
or lipid amphotericin B additional money is available
based on the total prescribed dosage. With the model
this total prescribed dosage was estimated for each of
these drugs for both the voriconazole arm and CAB
arm.
The total hospital charges for treatment of invasive
aspergillosis equal the sum of charges due to addi-
tional length of stay and additional charges of pre-
scription of voriconazole, caspofungin, or lipid
amphotericin B. Based on the distribution of underly-
ing conditions as observed in the GCA (307/602) study
a weighted average of hospital charges per treatment
arm was calculated. In both arms the distribution of
underlying condition was assumed as follows: 28%
allogeneic stem cell transplants, 7% autologous stem
cell transplants, 45% acute leukemia, 15% other
hematologic cancer, and 5% AIDS.
Cost-effectiveness  analysis. The cost-effectiveness
analysis was performed for total costs of both inpa-
tient and outpatient cost from the societal perspective
and the hospital perspective (inpatient costs). Both the
costs and effectiveness point estimates were presented
along with the uncertainty distribution of these means
reﬂected by the 2.5th percentile (p2.5) and 97.5th per-
centile (p97.5). For the cost-effectiveness parameters
the distribution of incremental costs and effectiveness
as well as acceptability curves are presented. The
uncertainty, as expressed by p2.5 and p97.5, and by
acceptability curves of the cost-effectiveness parame-
ters were estimated by means of 2nd order Monte
Carlo simulation. From distributions reﬂecting the
uncertainty of the input parameters a random value
was sampled, plugged in the model, and the corre-
sponding costs and effectiveness were calculated with
the model. This was repeated 1000 times to obtain dis-
tributions of the outcomes. The point estimate and the
uncertainty of the input parameters (e.g., the standard
errors for the efﬁcacy input parameters obtained from
trial, and assumed uncertainty of 20% for the resource
consumption parameters) were described by gamma
and beta distributions. In the base-case scenario no dis-
counting of costs or effects was applied. In additional
analysis discount rates of 3% and 5% were applied on
both costs and effects.
Results
Effects
Patients starting on voriconazole had a 52.9%
(48.2%; 58.1%) chance of a successful outcome at
12 weeks, which was higher than those starting on
CAB with 32.6% (28.2%; 37.8%). The 12-week sur-
vival of 70.9% (65.9%; 75.6%) for treatment of inva-
sive aspergillosis  with  voriconazole  corresponded  to
a mean survival of 174.4 (159.4; 191.3) life-weeks.
Treatment initiated with CAB resulted in a 12-week
survival of 58.6% (52.8; 63.5) and corresponded to a
mean survival of 119.4 (105.8; 132.5) life-weeks.
Costs
In Table 6 the treatment costs after 12 weeks and total
treatment costs are presented. The mean total treat-
ment costs (from lifelong model) for treatment initi-
ated with voriconazole were about €30,000 and when
CAB would have been used as ﬁrst-line therapy the
costs were about €27,000. Standardization by survival
resulted in costs of €172 per life-week for the vorico-
nazole arm, and €222 per life-week for the CAB arm.
The mean inpatient costs (hospital perspective from
lifelong model) for treatment initiated with voricona-
zole or CAB were about €26,000. The corresponding
costs per life-week were €151 for the voriconazole
arm, and €218 for the CAB arm.
Incremental Cost-Effectiveness
Table 7 shows the cost-effectiveness of voriconazole in
comparison to CAB in terms of 12-week success and
survival in life-weeks. From the societal perspective the
larger treatment costs at 12 weeks in combination with
a 20%-point effectiveness advantage for voriconazole
resulted in an incremental cost-effectiveness ratio of
about €25,000 for each additional successfully treated
patient. The incremental costs per life-week gained
with voriconazole in comparison to CAB were €62.34
(and corresponds to €3242 per life-year gained). From
the hospital perspective the incremental costs at
12 weeks for each additional successfully treated
Table 6 Treatment costs from societal perspective and hospital perspective
Voriconazole mean (€) (p2.5; p97.5) Conventional amphotericin B Mean (€) (p2.5; p97.5)
Societal perspective
12-week total cost 25,353 (18,550; 32,109) 20,092 (15,648; 25,297)
Total costs from lifelong model 30,026 (23,118; 37,947) 26,596 (21,259; 34,263)
Total costs per life-week from lifelong model 172 (133; 220) 222 (173; 288)
Hospital perspective
12-week inpatient costs 22,090 (16,395; 27,507) 19,637 (15,218; 25,177)
Inpatient costs from lifelong model 26,440 (20,489; 32,864) 26,058 (20,622; 34,152)
Total inpatient costs per life-week from lifelong model 151 (116; 192) 218 (171; 291)
p2.5 and p97.5, indicate 2.5th and 97.5 percentile of the uncertainty distribution, respectively.
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patient were about €12,000. The incremental costs per
life-week gained with voriconazole were €6.95 (and
corresponds to €361 per life-year gained). From the
limited societal perspective the probability that vorico-
nazole is cost-effective in comparison to CAB given a
willingness to pay of about €200 for each life-week
gained (corresponds to €11,000 per life-year) is about
90% (See Fig. 2). From the hospital perspective vori-
conazole is expected to be cost-effective for a willing-
ness to pay of about €100 for each life-week gained.
When discount rates of 3% and 5% per year were
applied to both costs and effects the incremental
effectiveness reduced to 49.0 and 45.7 weeks, respec-
tively, the corresponding incremental total costs from
the societal perspective were €3431 and €3432. The
incremental costs per life-week gained with voricona-
zole in comparison to CAB were €70.03 and €75.03,
respectively.
Hospital Charges Based on G-DRG System
The hospital charges with the DRG system are deﬁned
by the total dosage of voriconazole, caspofungin, or
lipid amphotericin B, and the underlying condition in
combination with the length of stay (For CAB no addi-
tional reimbursement “Zusatzentgelt” is granted
within the DRG system.
For the voriconazole arm the total average inpatient
dosage for voriconazole IV was 9.03 g (6.38; 11.63),
the inpatient dosage of oral voriconazole was 5.78 g
(4.27; 7.60). The total average inpatient dosage of
caspofungin and lipid amphotericin B are 0.12 g (0.09;
0.17) and 0.47 g (0.31; 0.69), respectively. The corre-
sponding reimbursed costs due to the use of these
drugs for a patient initially treated with voriconazole
are €9369 (5376; 11,829). For the CAB arm the total
average inpatient dosage of caspofungin and lipid
amphotericin B were 0.22 g (0.17; 0.30) and 1.26 g
(0.95; 1.67), respectively. The corresponding charged
costs due to the use of these drugs for a patient initially
treated with CAB are €5747 (4682; 7874).
According to the model the mean length of stay for
a patient treated with voriconazole was 39.9 days
(30.5; 49.9) and with CAB 45.5 days (36.1; 59.4). In
Table 8 the total charged costs available for the treat-
ment of aspergillosis infection (based on dosage and
length of stay) are presented stratiﬁed by different
DRGs for the underlying conditions. Based on the
underlying condition, the total charged costs vary from
Table 7 Incremental costs and incremental effectiveness, ICER, and cost-effectiveness of voriconazole versus conventional ampho-
tericin B
Incremental costs (€) mean (p2.5; p97.5) Incremental effectiveness mean (p2.5; p97.5) ICER (€) mean
Total treatment costs (societal perspective)
12-week horizon 5260 (−3905; 13,791) 0.20 (0.13; 0.27)%* 25,195 per successful patient
Lifetime horizon 3430 (−7452; 13,414) 55.0 (36.6; 74.6) weeks 62.34 per life-week gained
Inpatient costs (hospital perspective)
12-week horizon 2453 (−5369; 9728) 0.20 (0.13; 0.27)%* 12,084 per successful patient
Lifetime horizon 328 (−9308; 8921) 55.0 (36.6; 74.6) weeks 6.95 per life-week gained
*Incremental effectiveness expressed as percentage-points of additional successful patients.
ICER, incremental cost-effectiveness ratio; p2.5 and p97.5, indicate 2.5th and 97.5 percentile of the uncertainty distribution, respectively.
Figure 2 Acceptability curve of voriconazole
versus conventional amphotericin B as meas-
ured in life-weeks gained from the societal and
hospital perspectives.
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€19,030 (15,608; 22,685) (average from DRGs for
other hematologic cancer) to €44,791 (30,343;
60,222) (allogenic stem cell transplants) for treatment
initiated with voriconazole and from €17,462 (14,029;
22,511) (average from DRGs for other hematologic
cancer) to €49,837 (35,343; 71,155) (allogenic stem
cell transplants) for treatment initiated with CAB. The
weighted average of charged costs based on the distri-
bution of underlying conditions according to the GCA
(307/602) study was €29,616 (21,795; 37,969) for the
voriconazole arm and €30,686 (22,841; 42,226) for
the CAB arm.
Discussion
In  the  present  study  the  cost  and  cost-effectiveness
of voriconazole as ﬁrst-line treatment of invasive
aspergillosis in Germany was evaluated. According to
our modeling, the short-term advantage of ﬁrst-line
treatment with voriconazole in terms of successfully
treated patients as observed in the clinical trial [10]
was maintained in the long term. The model showed a
mean survival that is about 58 weeks longer than the
survival expected when CAB would have been the ﬁrst-
line choice of treatment for invasive aspergillosis. In
addition, voriconazole is also a more cost-effective
ﬁrst-line treatment than CAB. The higher total treat-
ment cost with voriconazole is acceptable given the
higher effectiveness. The incremental costs per life-
week gained with voriconazole in comparison to CAB
was €62, that is, €3224 per life-year gained, well below
an assumed willingness to pay threshold in Germany.
Voriconazole is more effective, more cost-effective,
and indicated as ﬁrst-line treatment of invasive
aspergillosis over CAB.
The second research question of this study was
whether the real costs of this favorable treatment are
fully reimbursed, especially given the recent change in
the reimbursement system in Germany effective since
beginning of 2005. Because the majority of treatment
costs are the inpatient costs and the recent changes in
reimbursement system reﬂect the inpatient situation,
this evaluation was limited to the inpatient costs. The
real inpatient costs (i.e., hospital perspective) for treat-
ment of invasive aspergillosis as estimated with the
model were about €26,000 for both voriconazole and
CAB. Invasive aspergillosis is a complication of several
different underlying diseases represented in different
DRGs. The charges related to an aspergillosis infection
are deﬁned by the underlying condition, which deﬁnes
the DRG, in combination with the length of stay, com-
plexity level, and the total dosage of voriconazole,
caspofungin, or lipid amphotericin B prescribed. Based
on the length of stay and total inpatient dosage of these
drugs suggested by the model, the expected hospital
charges for aspergillosis for different DRGs were cal-
culated. These costs varied depending on the underly-
ing condition between about €19,000 and €45,000 for
the voriconazole arm. (For the CAB arm comparable
ﬁgures were observed; see Table 8). Based on the
assumed distribution of underlying conditions, and
thereby the used DRGs, the average charges, and
therefore the reimbursed costs, were about €30,000.
Hence, on the average the inpatient costs for treatment
Table 8 Hospital charges based on German DRG 2005 by treatment arm and underlying condition
G-DRG 
codes [14]
Percentage
of patients
in model
assumed
(%)
Voriconazole Amphotericin B 
Charges
based on
LOS
Charges of total
dosage of 
voriconazole,
caspofungin, or lipid
amphotericin B
Total charges 
(p2.5; p97.5)
Charges
based on
LOS
Charges of total
dosage of 
voriconazole, 
caspofungin, or lipid
amphotericin B
Total charges 
(p2.5; p97.5)
Acute
leukemia
R60A-R60E
R63A-R63E
45 13,996 9369 23,365 (18.052;
29,040)
17,184 5747 22,931 (17,601;
30,770)
Other
hematologic
cancer
R01A R01B
R02Z R03Z
R04A R04B
15 9,662 9369 19,030 (15,608; 
22,685)
11,715 5747 17,462 (14,029;
22,511)
R05Z R06Z
R07Z R08Z
R09Z R10Z
R11A-R15Z
R61A-R62C
Allogeneic
stem cell
transplants
A04A-A04E 28 35,422 9369 44,791 (30,343; 
60,222)
44,090 5747 49,837 (35,343
71,155)
Autologous
stem cell
transplants
A15A-A15D 7 29,572 9369 38,940 (29,113; 
49,437)
35,468 5747 41,215 (31,356;
55,715)
AIDS S62Z-S65Z 5 12,662 9369 19,597 (15,933 
23,510)
15,356 5747 18,173 (14,497;
23,579)
Total 100 20,337 9369 29,616 (21,795 
37,969)
25,048 5747 30,686 (22,841; 
42.226)
G-DRG, German diagnosis-related group; LOS, length of stay.
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of an invasive aspergillosis infection are expected to be
reimbursed by the G-DRG 2005 system. Because the
model estimates the average inpatient costs (from the
hospital perspective) per patient for a cohort of
patients with different underlying conditions it pro-
vides only limited information when the average inpa-
tients costs are compared with the charges per DRG
code for each of the underlying conditions; for an
appropriate comparison subgroup analysis by under-
lying condition should be performed. Anyhow, the dis-
tribution of underlying conditions as used in the
present study shows that the charges cover costs.
Prospective budgeting according to the DRG system
gives strong economic incentives to hospitals but also
bares considerable risks for hospitals when treating
severe, resource-intensive, and costly indications. Ade-
quate reimbursement for these indications ensures that
hospitals take the risk of continuously investing in, for
example, specialized transplant units to deliver ade-
quate and high-level care for severely diseased patients.
For high-level-care hospitals/specialized hospital units
this can only be achieved if frequently occurring com-
plications like aspergillosis are adequately represented
in the DRG system.
Model issues
To develop a decision analytic model for the treatment
of invasive aspergillosis the practice of invasive
aspergillosis was simpliﬁed, and several assumptions
were made with respect to the structure of the model.
Treatment patterns were reﬂected with a decision tree.
According to the experts treatment switches occur in
the ﬁrst 12 weeks of treatment, and therefore it was
valid that the structure of the model was not able to
capture treatment switches after week 12.
In the 12-week GCA (307/602) study an average of
0.51 switches in the voriconazole arm and 1.35 in the
CAB arm were observed. Alternatively, 13% of vori-
conazole patients and 40% of CAB patients had two
or more switches to OLATs [17]. By structure the deci-
sion tree allows for one switch in treatment. In the
model multiple switches are captured by the propor-
tional switch distributions, which are a reﬂection of
days on a particular OLAT. A consequence of this
approach is that the inpatient length of treatment and
therefore various resource utilizations are underesti-
mated. With one treatment switch in the model the
total length of stay among switch patients equals time
to switch plus the length of stay post treatment switch
according to the proportional switch distributions and
the weighted average of one OLAT length of treat-
ment. The approach does not include the time to
switch from the ﬁrst to the second switch for example.
Hence, the model probably underestimates the total
costs for patients with multiple switches, with proba-
bly a larger underestimation for the CAB arm as
according to the GCA (307/602) study more OLATs
have been used in this therapy arm compared with the
voriconazole arm.
The 12-week results as observed in the GCA (307/
602) study were extrapolated into a lifelong model by
which survival time could be estimated. We assumed
that the weekly probabilities that reﬂect a “transition”
from failure to success or death, or a “transition” from
success to death beyond week 12 were constant over
time. Hence, the probability density function (PDF) of
survival time given success or failure, and the PDF of
success are described by an exponential distribution.
As far as we know the literature does not provide
information that invalidates or supports this assump-
tion of an exponential distribution. Nevertheless,
because the majority of transitions from failure to suc-
cess or death have occurred before week 12, the type of
distribution reﬂecting the development of transition
probabilities from failure to success or death over time
beyond week 12 has only limited impact on the results.
The majority of transitions after week 12 reﬂect dying
from the underlying condition, and given the lack of
information regarding long-term distributions of sur-
vival time, we assumed an exponential distribution for
survival in accordance with the opinion of the expert
panel.
For switch patients the extracted success, failure,
and mortality probability per week for a given treat-
ment pathway based on the 12-week results may have
resulted in an underestimation of survival times. For
these patients, the weekly success probability of the
OLAT is higher than the ﬁrst-line therapy, either
because of a more potent drug or because of the fact
that the drug is better tolerated. Hence, for a proper
extrapolation the results of the OLAT for treatment
pathway should be used. Unfortunately, this informa-
tion was not available. Patients initially on CAB expe-
rience the most treatments switches, and by using the
combined results of ﬁrst-line treatment and OLAT the
underestimation of the long-term survival among these
patients is expected to be the largest. Hence, the incre-
mental survival of voriconazole in comparison to CAB
might be overestimated.
No difference was made in the medical resource
consumption for successes and failures by type of
treatment switch as a result of the fact that: 1) esti-
mates on medical resource consumption for all the dif-
ferent subgroups from the GCA (307/602) study were
characterized  by  large  uncertainty,  and  2)  therefore,
it was impossible to obtain reliable information on
resource consumption for both success and failures
among the different subgroups from the experts. The
use of aggregate level information independent of the
outcome at 12 weeks has probably resulted in an over-
estimation of resource consumption and costs for vor-
iconazole in comparison to CAB because a higher
proportion of successes were observed in the vorico-
nazole arm and it is expected that successes are
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observed earlier with voriconazole than successes with
CAB.
In conclusion, the ﬁrst-line treatment of invasive
aspergillosis with voriconazole in Germany is a cost-
effective choice. From the hospital perspective the
inpatient costs for voriconazole and CAB are compa-
rable, and are expected to be reimbursed based on the
German DRG system 2005. Hence, economic argu-
ments do not interfere with the German guidelines that
state that voriconazole is ﬁrst choice of treatment of
invasive aspergillosis [1].
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